Preclinical drug response metric based on cellular response phenotype provides better pharmacogenomic variables with phenotype relevance

Abstract

Current drug-response metrics based on viability or apparent growth rates are limited by their dependency on the assay duration and lack of reflections regarding actual cellular drug-response phenotypes. To resolve these limitations, we evaluated the contribution of each cellular response phenotype to a drug on the overall growth behavior. This provides a time-independent phenotype metric which can reveal the mechanisms underlying growth inhibition of specific cells by a given drug.